权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

University of Michigan Quantitative Co-Clinical Imaging Research Resource

密歇根大学定量联合临床成像研究资源

基本信息

批准号：
10687996
负责人：
THOMAS L CHENEVERT
金额：
$ 61.58万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-01 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10687996
关键词：
Abdomen Address Anatomy Animals Architecture Autopsy Biopsy Bone Marrow Bone Marrow Cells Bone Marrow Diseases Bone marrow biopsy Cancer Detection Cells Cellularity Chronic Clinical Clinical Medicine Clinical Trials Code Communities Computer software Confidence Intervals DNA Sequence Alteration Data Data Set Deposition Development Diffusion Disease Dryness Ensure Environment FDA approved Fatty acid glycerol esters Fibrosis Genetic Genomics Goals Hematologic Neoplasms Hematopoietic Neoplasms Hematopoietic stem cells Heterogeneity Histology Human Image Image Analysis Imaging Phantoms Imaging Techniques Institution Internet Investigational Therapies JAK1 gene Magnetic Resonance Imaging Malignant Neoplasms Maps Measurement Measures Methods Michigan Multi-Institutional Clinical Trial Mus Myelofibrosis Myeloproliferative disease Oncologist Oncology Output Pain Patient Care Patients Pharmaceutical Preparations Physicians Pre-Clinical Model Preclinical Drug Development Prediction of Response to Therapy Procedures Protocols documentation Protons Publications Reproducibility Research Research Personnel Resources Sampling Errors Scanning Severities Severity of illness Site Skeleton Spleen Standardization Techniques Testing The Cancer Imaging Archive Three-Dimensional Imaging Time Tissues Translations Universities Validation Vendor Water Work bone cancer therapy clinical imaging co-clinical trial density disease heterogeneity driver mutation drug development drug testing experience human imaging human subject image processing imaging biomarker imaging modality imaging study improved inhibitor millimeter mouse model novel therapeutics patient population pre-clinical preclinical imaging preclinical trial quantitative imaging response response biomarker standard of care success systemic inflammatory response treatment response user-friendly web site

项目摘要

PROJECT SUMMARY/ABSTRACT Quantitative imaging methods to detect cancer and assess response to therapy are cornerstones of pre-clinical drug development, clinical trials, and patient care. Success of quantitative imaging in oncology relies on standardization of protocols for image acquisition and analysis to ensure reproducibility within a single site over time and across institutions for multi-site clinical trials. Work by our group and others in the Quantitative Imaging Network and Quantitative Imaging Biomarkers Alliance continues to advance standardization procedures for clinical imaging. However, similar rigor has not been applied to pre-clinical imaging studies of cancer therapy in mice. The disconnect between standardization and validation methods incorporated into imaging studies for humans versus mice contributes to ongoing challenges with reproducibility in drug development and successful translation of new drugs to clinical medicine. To ensure direct, quantitative comparisons between pre-clinical and clinical imaging, we will establish a resource for quantitative MRI of bone marrow composition and architecture in myelofibrosis (MF), a chronic hematologic cancer marked by progressive fibrosis and destruction of bone marrow. This resource will extend quantitative imaging into hematologic cancers, a group of malignancies understudied and underserved by imaging because current methods generate largely qualitative data that cannot be used reliably as biomarkers for response to therapy. We will analyze key metrics of bone marrow disease using FDA-approved MRI sequences included in standard software packages for pre-clinical 7T and clinical 3T scanners: 1) bone marrow composition and cellularity (quantitative Dixon technique for fat/water); 2) replacement of normal bone marrow cells and bone trabecula (mobility of water (diffusion, DWI)); and 3) extent and severity of fibrosis (magnetization transfer (MT)). As part of standardization procedures for both mouse and human imaging, we will measure repeatability of imaging data using phantoms for each MRI sequence and test/retest imaging procedures for mouse and human subjects to establish confidence intervals. We also will standardize workflow for quantifying bone marrow MRI data with parametric response mapping (PRM), a voxel-wise image processing method we devised to capture spatial and temporal heterogeneity of imaging data during treatment. After establishing standard operating procedures for quantitative bone marrow MRI (Aim 1), we will apply these methods to co-clinical trials with standard-of-care and investigational therapies for MF, matching driver mutations for MF present in our patient population with our mouse model (Aim 2). To disseminate these methods to the imaging community, we will post standard operating procedures for MRI protocols, mouse models of MF, and PRM of bone marrow MRI data (Aim 3). We also will deposit curated imaging data in the TCIA, enabling other investigators to mine these data and test new hypotheses. Overall, this resource will reduce variability in quantitative bone marrow MRI in both mice and humans, improving the ability to reliably implement these imaging biomarkers to advance co-clinical trials and drug development MF and likely other hematologic malignancies.

项目总结/文摘